Evidence map›Paper›PMID 27688803›Full record

ArticleBlood2016

Antigen modulation as a potential mechanism of anti-KEL immunoprophylaxis in mice.

Jingchun Liu, Manjula Santhanakrishnan, Prabitha Natarajan, David R Gibb, Stephanie C Eisenbarth, Christopher A Tormey, Alexa J Siddon, Sean R Stowell, Donald R Branch, Jeanne E Hendrickson

Open access · bronzeAbstract read
In one paragraph

Article in Blood, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 38 citations in OpenAlex.

  1. Serine protease HtrA promotesScience advances · 2026
    Article
  2. Analysis of Erythrocyte Membrane Alloantigens.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  3. The Immunology of Transfusion Medicine: Past, Present, and Future.Methods in molecular biology (Clifton, N.J.) · 2026
    Review
  4. Article
  5. Article
  6. B Cell Responses to the Placenta and Fetus.Annual review of pathology · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Jingchun LiuDepartment of Laboratory Medicine and.
Manjula SanthanakrishnanDepartment of Laboratory Medicine and.
Prabitha NatarajanDepartment of Laboratory Medicine and.
David R GibbDepartment of Laboratory Medicine and.
Stephanie C EisenbarthDepartment of Laboratory Medicine and.
Christopher A TormeyDepartment of Laboratory Medicine and.
Alexa J SiddonDepartment of Laboratory Medicine and.
Sean R StowellDepartment of Pathology and Laboratory Medicine, Emory University, Atlanta, GA.
Donald R BranchCentre for Innovation, Canadian Blood Services, Toronto, ON, Canada; and.
Jeanne E HendricksonDepartment of Laboratory Medicine and.
Yale University · USCanadian Blood Services · CAEmory University · USVA Connecticut Healthcare System · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
IMMUNOHEMATOLOGY/TRANSFUSION MEDICINE RESEARCH TRAININGT32HL007974 · NHLBI · YALE UNIVERSITY · PI JEANNE E HENDRICKSON, Diane S Krause · 2001 to 2026
$8.1M
Protecting Fetuses and Newborns from Maternal RBC AlloantibodiesR01HL126076 · NHLBI · YALE UNIVERSITY · PI HENDRICKSON, JEANNE E · 2014 to 2018
$2.1M
NCATS NIH HHS UL1 TR001863NHLBI NIH HHS R01 HL126076NHLBI NIH HHS T32 HL007974
6 · The paper itself

Abstract

Red blood cell (RBC) alloimmunization is a serious complication of transfusion or pregnancy. Despite the widespread use of Rh immune globulin to prevent pregnancy associated anti-D alloimmunization, its mechanism of action remains elusive. We have previously described a murine model in which immunoprophylaxis with polyclonal anti-KEL sera prevents alloimmunization in wild-type recipients transfused with transgenic murine RBCs expressing the human KEL glycoprotein. To investigate the mechanism of action, we have now evaluated the outcome of immunoprophylaxis treatment in mice lacking Fcγ receptors (FcγRs), complement (C3), both, or none. Whereas polyclonal anti-KEL sera completely prevented alloimmunization in wild-type and single-knockout (KO) mice lacking FcγRs or C3, double-KO mice lacking both FcγRs and C3 became alloimmunized despite immunoprophylaxis. Rapid clearance of essentially all transfused RBCs with detectable KEL glycoprotein antigen occurred within 24 hours in wild-type and single-KO recipients treated with immunoprophylaxis, with the transfused RBCs remaining in circulation having minimal KEL glycoprotein antigen detectable by flow cytometry or western blot. In contrast, transfused RBCs with the KEL glycoprotein antigen fully intact continued to circulate for days in double-KO mice despite treatment with immunoprophylaxis. Further, in vitro phagocytosis assays showed no consumption of opsonized murine RBCs by double-KO splenocytes. Taken in combination, our data suggest that modulation of the KEL antigen (and potentially RBC clearance) by redundant recipient pathways involving both FcγRs and C3 may be critical to the mechanism of action of polyclonal anti-KEL immunoprophylaxis. These findings could have implications for the development of immunoprophylaxis programs in humans.

Indexed as

ImmunizationAnimalsAntibodies, Anti-IdiotypicAntigensBlood TransfusionBlotting, WesternComplement C3Crosses, GeneticErythrocytesHumansMembrane GlycoproteinsMetalloendopeptidasesMice, Inbred C57BLMice, KnockoutOpsonin ProteinsPhagocytosisAntibodies, Anti-IdiotypicAntigensComplement C3KEL protein, humanMembrane GlycoproteinsMetalloendopeptidasesOpsonin ProteinsReceptors, Immunologic

Identifiers

PMID27688803
PMCPMC5201095
OpenAlexW2412828514

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.